The Potential of GLP-1 Medications Treating and Curing Sleep Apnea

The evidence strongly suggests that GLP-1 medications, particularly tirzepatide, hold significant promise in reducing the severity of obstructive sleep apnea in individuals with obesity. Clinical trials and meta-analyses have demonstrated substantial reductions in the Apnea-Hypopnea Index (AHI), along with significant weight loss and improvements in related cardiometabolic risk factors. The recent FDA approval of tirzepatide (Zepbound) as the first medication for sleep apnea  marks a major advancement in the field.The potential benefits of GLP-1s extend beyond just AHI reduction, with indications of improved subjective sleep quality and reduced daytime sleepiness. While there is no direct evidence in the reviewed material regarding the reduction of snoring as a primary outcome, it is plausible that this symptom may also improve as a secondary effect of weight loss and improved airway patency.This is the official podcast of GLP-1 Tribe - the patient led community for GLP-1 medications. https://glp1tribe.com/